{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:05:50Z","timestamp":1790456750200,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP). Moreover, we aimed to describe the maternal factors associated with NVP and antiemetic use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The data consist of pregnancies with a live birth(s) within an IMRD\u2010UK registered GP practice. Descriptive statistics were used to investigate patterns of ondansetron use in pregnancy and to describe maternal characteristics associated with NVP and antiemetic drug utilization. We differentiate first\u2010 from second\u2010line use during pregnancy using antiemetic prescription pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The dataset included 733\u2009633 recorded complete pregnancies from 2005 to 2019. NVP diagnosis and ondansetron prescription prevalence increased from 2.7% and 0.1% in 2005 to 4.8% and 2.5% in 2019 respectively. Over the period 2015\u20132019, the most common oral daily dosages were 4\u00a0mg\/d (8.5%), 8\u00a0mg\/d (37.1%), 12\u2009mg\/d (37.5%) and between 16 and 24\u2009mg\/d (16.9%). Prescription of ondansetron was initiated during the first trimester of pregnancy in 40% of the cases and was moderately used as a first\u2010line therapy (2.8%), but preferred choice of second\u2010line therapy. Women with mental health disorders, asthma and\/or prescribed folic acid were more likely to experience NVP and use antiemetics in pregnancy than their counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that ondansetron is increasingly used off\u2010label to treat NVP during pregnancy, also in the first trimester and before other prescription antiemetics have been prescribed. Several maternal comorbidities and folic acid use were more common among women experiencing NVP and using antiemetics, including ondansetron.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.15370","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:29:46Z","timestamp":1651181386000},"page":"4526-4539","source":"Crossref","is-referenced-by-count":15,"title":["Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice"],"prefix":"10.1111","volume":"88","author":[{"given":"Jim","family":"Slattery","sequence":"first","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-2326","authenticated-orcid":false,"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Candore","sequence":"additional","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flynn","sequence":"additional","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"},{"name":"Medicines Monitoring Unit University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[{"name":"Data Analytics Taskforce European Medicines Agency  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences University of Oslo  Oslo Norway"},{"name":"Department of Child Health and Development Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007575.pub3"},{"issue":"2","key":"e_1_2_12_3_1","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis","volume":"20","author":"Einarson TR","year":"2013","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02024-0"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471\u20100528.2011.03023.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002456"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2016.08.009"},{"key":"e_1_2_12_8_1","unstructured":"European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf. Assessed 22 October 2021."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S287892"},{"key":"e_1_2_12_10_1","unstructured":"Royal College of Obstetricians & Gynaecologists.The management of nausea and vomiting of pregnancy and hyperemesis gravidarum. Green\u2010top guidelines No. 69. June2016."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2017.1342805"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002456"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4185"},{"key":"e_1_2_12_14_1","unstructured":"The Norwegian Society of Obstetrics and Gynecology.Veileder i f\u00f8dselshjelp [Obstetric guidelines issued by the Norwegian Society of Obstetrics and Gynaecology];2020;ePub. ISBN 978\u201382\u2013692382\u20100\u20104."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5329"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz255"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002679"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2018.10.010"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18307"},{"key":"e_1_2_12_20_1","unstructured":"See linkhttps:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf. Accessed 22 December 2020."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.14236\/jhi.v19i4.820"},{"key":"e_1_2_12_22_1","unstructured":"See link.https:\/\/digital.nhs.uk\/services\/terminology-and-classifications\/read-codes. Assessed 22 October 2021."},{"key":"e_1_2_12_23_1","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis","volume":"20","author":"Einarson TR","year":"2013","journal-title":"J Popul there Clin Parmacol"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2010.05.009"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2014.02.012"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2011.582904"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew128"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15370","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:47:19Z","timestamp":1692794839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/bcp.15370"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15370","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}